Retroviral transfer of the glucocerebrosidase gene into CD34+ cells from patients with Gaucher disease: In vivo detection of transduced cells without myeloablation

Cynthia E. Dunbar, Donald B. Kohn, Raphael Schiffmann, Norman W. Barton, Jan Nolta, Joan A. Esplin, Michael Pensiero, Zhifeng Long, Chris Lockey, Robert V B Emmons, Susie Csik, Susan Leitman, Connie B. Krebs, Charles Carter, Roscoe O. Brady, Stefan Karlsson

Research output: Contribution to journalArticle

149 Citations (Scopus)

Abstract

Retroviral gene transfer of the glucocerebrosidase gene to hematopoietic progenitor and stem cells has shown promising results in animal models and corrected the enzyme deficiency in cells from Gaucher patients in vitro. Therefore, a clinical protocol was initiated to explore the safety and feasibility of retroviral transduction of peripheral blood (PB) or bone marrow (BM) CD34+ cells with the G1Gc vector. This vector uses the viral LTR promoter to express the human glucocerebrosidase cDNA. Three adult patients have been entered with follow-up of 6-15 months. Target cells were G-CSF-mobilized and CD34-enriched PB cells or CD34-enriched steady state BM cells, and were transduced ex vivo for 72 hr. Patient 1 had PB cells transduced in the presence of autologous stromal marrow cells. Patient 2 had PB cells transduced in the presence of autologous stroma, IL-3, IL-6, and SCF. Patient 3 had BM cells transduced in the presence of autologous stroma, IL-3, IL-6, and SCF. At the end of transduction, the cells were collected and infused immediately without any preparative treatment of the patients. The transduction efficiency of the CD34+ cells at the end of transduction was approximately 1, 10, and 1 for patients 1, 2, and 3, respectively, as estimated by semiquantitative PCR on bulk samples and PCR analysis of individual hematopoietic colonies. Gene marking in vivo was demonstrated in patients 2 and 3. Patient 2 had vector-positive PB granulocytes and mononuclear bone marrow cells at 1 month postinfusion and positive PB mononuclear cells at 2 and 3 months postinfusion. Patient 3 had a positive BM sample at 1 month postinfusion but was negative thereafter. These results indicate that gene-marked cells can engraft and persist for at least 3 months postinfusion, even without myeloablation. However, the level of corrected cells (< 0.02%) is too low to result in any clinical benefit, and glucocerebrosidase enzyme activity did not increase in any patient following infusion of transduced cells. Modifications of vector systems and transduction conditions, along with partial myeloablation to allow higher levels of engraftment, may be necessary to achieve beneficial levels of correction in patients with Gaucher disease.

Original languageEnglish (US)
Pages (from-to)2629-2640
Number of pages12
JournalHuman Gene Therapy
Volume9
Issue number17
DOIs
StatePublished - Nov 20 1998
Externally publishedYes

Fingerprint

Glucosylceramidase
Gaucher Disease
Genes
Bone Marrow Cells
Blood Cells
Interleukin-3
Hematopoietic Stem Cells
Interleukin-6
Bone Marrow
Polymerase Chain Reaction
Granulocyte Colony-Stimulating Factor
Enzymes
Stromal Cells
Clinical Protocols
Granulocytes

ASJC Scopus subject areas

  • Genetics

Cite this

Retroviral transfer of the glucocerebrosidase gene into CD34+ cells from patients with Gaucher disease : In vivo detection of transduced cells without myeloablation. / Dunbar, Cynthia E.; Kohn, Donald B.; Schiffmann, Raphael; Barton, Norman W.; Nolta, Jan; Esplin, Joan A.; Pensiero, Michael; Long, Zhifeng; Lockey, Chris; Emmons, Robert V B; Csik, Susie; Leitman, Susan; Krebs, Connie B.; Carter, Charles; Brady, Roscoe O.; Karlsson, Stefan.

In: Human Gene Therapy, Vol. 9, No. 17, 20.11.1998, p. 2629-2640.

Research output: Contribution to journalArticle

Dunbar, CE, Kohn, DB, Schiffmann, R, Barton, NW, Nolta, J, Esplin, JA, Pensiero, M, Long, Z, Lockey, C, Emmons, RVB, Csik, S, Leitman, S, Krebs, CB, Carter, C, Brady, RO & Karlsson, S 1998, 'Retroviral transfer of the glucocerebrosidase gene into CD34+ cells from patients with Gaucher disease: In vivo detection of transduced cells without myeloablation', Human Gene Therapy, vol. 9, no. 17, pp. 2629-2640. https://doi.org/10.1089/10430349850019463
Dunbar, Cynthia E. ; Kohn, Donald B. ; Schiffmann, Raphael ; Barton, Norman W. ; Nolta, Jan ; Esplin, Joan A. ; Pensiero, Michael ; Long, Zhifeng ; Lockey, Chris ; Emmons, Robert V B ; Csik, Susie ; Leitman, Susan ; Krebs, Connie B. ; Carter, Charles ; Brady, Roscoe O. ; Karlsson, Stefan. / Retroviral transfer of the glucocerebrosidase gene into CD34+ cells from patients with Gaucher disease : In vivo detection of transduced cells without myeloablation. In: Human Gene Therapy. 1998 ; Vol. 9, No. 17. pp. 2629-2640.
@article{3d1d59674b25488aa2834870cbf4ec85,
title = "Retroviral transfer of the glucocerebrosidase gene into CD34+ cells from patients with Gaucher disease: In vivo detection of transduced cells without myeloablation",
abstract = "Retroviral gene transfer of the glucocerebrosidase gene to hematopoietic progenitor and stem cells has shown promising results in animal models and corrected the enzyme deficiency in cells from Gaucher patients in vitro. Therefore, a clinical protocol was initiated to explore the safety and feasibility of retroviral transduction of peripheral blood (PB) or bone marrow (BM) CD34+ cells with the G1Gc vector. This vector uses the viral LTR promoter to express the human glucocerebrosidase cDNA. Three adult patients have been entered with follow-up of 6-15 months. Target cells were G-CSF-mobilized and CD34-enriched PB cells or CD34-enriched steady state BM cells, and were transduced ex vivo for 72 hr. Patient 1 had PB cells transduced in the presence of autologous stromal marrow cells. Patient 2 had PB cells transduced in the presence of autologous stroma, IL-3, IL-6, and SCF. Patient 3 had BM cells transduced in the presence of autologous stroma, IL-3, IL-6, and SCF. At the end of transduction, the cells were collected and infused immediately without any preparative treatment of the patients. The transduction efficiency of the CD34+ cells at the end of transduction was approximately 1, 10, and 1 for patients 1, 2, and 3, respectively, as estimated by semiquantitative PCR on bulk samples and PCR analysis of individual hematopoietic colonies. Gene marking in vivo was demonstrated in patients 2 and 3. Patient 2 had vector-positive PB granulocytes and mononuclear bone marrow cells at 1 month postinfusion and positive PB mononuclear cells at 2 and 3 months postinfusion. Patient 3 had a positive BM sample at 1 month postinfusion but was negative thereafter. These results indicate that gene-marked cells can engraft and persist for at least 3 months postinfusion, even without myeloablation. However, the level of corrected cells (< 0.02{\%}) is too low to result in any clinical benefit, and glucocerebrosidase enzyme activity did not increase in any patient following infusion of transduced cells. Modifications of vector systems and transduction conditions, along with partial myeloablation to allow higher levels of engraftment, may be necessary to achieve beneficial levels of correction in patients with Gaucher disease.",
author = "Dunbar, {Cynthia E.} and Kohn, {Donald B.} and Raphael Schiffmann and Barton, {Norman W.} and Jan Nolta and Esplin, {Joan A.} and Michael Pensiero and Zhifeng Long and Chris Lockey and Emmons, {Robert V B} and Susie Csik and Susan Leitman and Krebs, {Connie B.} and Charles Carter and Brady, {Roscoe O.} and Stefan Karlsson",
year = "1998",
month = "11",
day = "20",
doi = "10.1089/10430349850019463",
language = "English (US)",
volume = "9",
pages = "2629--2640",
journal = "Human Gene Therapy",
issn = "1043-0342",
publisher = "Mary Ann Liebert Inc.",
number = "17",

}

TY - JOUR

T1 - Retroviral transfer of the glucocerebrosidase gene into CD34+ cells from patients with Gaucher disease

T2 - In vivo detection of transduced cells without myeloablation

AU - Dunbar, Cynthia E.

AU - Kohn, Donald B.

AU - Schiffmann, Raphael

AU - Barton, Norman W.

AU - Nolta, Jan

AU - Esplin, Joan A.

AU - Pensiero, Michael

AU - Long, Zhifeng

AU - Lockey, Chris

AU - Emmons, Robert V B

AU - Csik, Susie

AU - Leitman, Susan

AU - Krebs, Connie B.

AU - Carter, Charles

AU - Brady, Roscoe O.

AU - Karlsson, Stefan

PY - 1998/11/20

Y1 - 1998/11/20

N2 - Retroviral gene transfer of the glucocerebrosidase gene to hematopoietic progenitor and stem cells has shown promising results in animal models and corrected the enzyme deficiency in cells from Gaucher patients in vitro. Therefore, a clinical protocol was initiated to explore the safety and feasibility of retroviral transduction of peripheral blood (PB) or bone marrow (BM) CD34+ cells with the G1Gc vector. This vector uses the viral LTR promoter to express the human glucocerebrosidase cDNA. Three adult patients have been entered with follow-up of 6-15 months. Target cells were G-CSF-mobilized and CD34-enriched PB cells or CD34-enriched steady state BM cells, and were transduced ex vivo for 72 hr. Patient 1 had PB cells transduced in the presence of autologous stromal marrow cells. Patient 2 had PB cells transduced in the presence of autologous stroma, IL-3, IL-6, and SCF. Patient 3 had BM cells transduced in the presence of autologous stroma, IL-3, IL-6, and SCF. At the end of transduction, the cells were collected and infused immediately without any preparative treatment of the patients. The transduction efficiency of the CD34+ cells at the end of transduction was approximately 1, 10, and 1 for patients 1, 2, and 3, respectively, as estimated by semiquantitative PCR on bulk samples and PCR analysis of individual hematopoietic colonies. Gene marking in vivo was demonstrated in patients 2 and 3. Patient 2 had vector-positive PB granulocytes and mononuclear bone marrow cells at 1 month postinfusion and positive PB mononuclear cells at 2 and 3 months postinfusion. Patient 3 had a positive BM sample at 1 month postinfusion but was negative thereafter. These results indicate that gene-marked cells can engraft and persist for at least 3 months postinfusion, even without myeloablation. However, the level of corrected cells (< 0.02%) is too low to result in any clinical benefit, and glucocerebrosidase enzyme activity did not increase in any patient following infusion of transduced cells. Modifications of vector systems and transduction conditions, along with partial myeloablation to allow higher levels of engraftment, may be necessary to achieve beneficial levels of correction in patients with Gaucher disease.

AB - Retroviral gene transfer of the glucocerebrosidase gene to hematopoietic progenitor and stem cells has shown promising results in animal models and corrected the enzyme deficiency in cells from Gaucher patients in vitro. Therefore, a clinical protocol was initiated to explore the safety and feasibility of retroviral transduction of peripheral blood (PB) or bone marrow (BM) CD34+ cells with the G1Gc vector. This vector uses the viral LTR promoter to express the human glucocerebrosidase cDNA. Three adult patients have been entered with follow-up of 6-15 months. Target cells were G-CSF-mobilized and CD34-enriched PB cells or CD34-enriched steady state BM cells, and were transduced ex vivo for 72 hr. Patient 1 had PB cells transduced in the presence of autologous stromal marrow cells. Patient 2 had PB cells transduced in the presence of autologous stroma, IL-3, IL-6, and SCF. Patient 3 had BM cells transduced in the presence of autologous stroma, IL-3, IL-6, and SCF. At the end of transduction, the cells were collected and infused immediately without any preparative treatment of the patients. The transduction efficiency of the CD34+ cells at the end of transduction was approximately 1, 10, and 1 for patients 1, 2, and 3, respectively, as estimated by semiquantitative PCR on bulk samples and PCR analysis of individual hematopoietic colonies. Gene marking in vivo was demonstrated in patients 2 and 3. Patient 2 had vector-positive PB granulocytes and mononuclear bone marrow cells at 1 month postinfusion and positive PB mononuclear cells at 2 and 3 months postinfusion. Patient 3 had a positive BM sample at 1 month postinfusion but was negative thereafter. These results indicate that gene-marked cells can engraft and persist for at least 3 months postinfusion, even without myeloablation. However, the level of corrected cells (< 0.02%) is too low to result in any clinical benefit, and glucocerebrosidase enzyme activity did not increase in any patient following infusion of transduced cells. Modifications of vector systems and transduction conditions, along with partial myeloablation to allow higher levels of engraftment, may be necessary to achieve beneficial levels of correction in patients with Gaucher disease.

UR - http://www.scopus.com/inward/record.url?scp=0032553681&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032553681&partnerID=8YFLogxK

U2 - 10.1089/10430349850019463

DO - 10.1089/10430349850019463

M3 - Article

C2 - 9853529

AN - SCOPUS:0032553681

VL - 9

SP - 2629

EP - 2640

JO - Human Gene Therapy

JF - Human Gene Therapy

SN - 1043-0342

IS - 17

ER -